US 5019368A
· Epstein et al.
· 1991
[cited by applicant]
US 5283173A
· Fields et al.
· 1994
[cited by applicant]
US 5468614A
· Fields et al.
· 1995
[cited by applicant]
US 5641863A
· Schreiber et al.
· 1997
[cited by applicant]
US 5641875A
· Schreiber et al.
· 1997
[cited by applicant]
US 5747498A
· Schnur et al.
· 1998
[cited by applicant]
US 5776910A
· Schreiber et al.
· 1998
[cited by applicant]
US 5821071A
· Schreiber et al.
· 1998
[cited by applicant]
US 6068983A
· Schreiber et al.
· 2000
[cited by applicant]
US 6475997B1
· Schreiber et al.
· 2002
[cited by applicant]
US 6630313B2
· Fadok et al.
· 2003
[cited by applicant]
US 7195761B2
· Holtzman et al.
· 2007
[cited by applicant]
US 7247303B2
· Thorpe et al.
· 2007
[cited by applicant]
US 7892544B2
· Pfeifer et al.
· 2011
[cited by applicant]
US 7910333B2
· Chilcote et al.
· 2011
[cited by applicant]
US 8025878B2
· Gellerfors et al.
· 2011
[cited by applicant]
US 8119772B2
· Yang et al.
· 2012
[cited by applicant]
US 8496938B2
· Smith et al.
· 2013
[cited by applicant]
US 8940276B2
· Weihofen et al.
· 2015
[cited by applicant]
US 8956616B2
· Thorpe et al.
· 2015
[cited by applicant]
US 20030072743A1
· Albert et al.
· 2003
[cited by applicant]
US 20030095962A1
· Ueda et al.
· 2003
[cited by applicant]
US 20030130218A1
· Schreiber et al.
· 2003
[cited by applicant]
US 20060002940A1
· Stevenson
· 2006
[cited by applicant]
US 20060257359A1
· Francois et al.
· 2006
[cited by applicant]
US 20070258897A1
· Devitt et al.
· 2007
[cited by applicant]
US 20080213216A1
· Schreiber et al.
· 2008
[cited by applicant]
US 20110165649A1
· Tyler et al.
· 2011
[cited by applicant]
US 20130071414A1
· Dotti et al.
· 2013
[cited by applicant]
US 20140162290A1
· Watanabe et al.
· 2014
[cited by applicant]
US 20170151281A1
· Wagner et al.
· 2017
[cited by applicant]
US 20170209492A1
· June et al.
· 2017
[cited by applicant]
US 20180186855A1
· Rosenthal
· 2018
[cited by applicant]
US 20180291089A1
· Epstein et al.
· 2018
[cited by applicant]
US 20180319862A1
· Thompson et al.
· 2018
[cited by applicant]
US 20200055917A1
· Corey
· 2020
[cited by applicant]
US 20210015865A1
· Corey
· 2021
[cited by applicant]
US 20210024607A1
· Corey et al.
· 2021
[cited by applicant]
US 20210253696A1
· Corey et al.
· 2021
[cited by applicant]
US 20240285684A1
· Corey et al.
· 2024
[cited by applicant]
CN 106749675A
· 2017
[cited by applicant]
EP 0566226B1
· 1995
[cited by applicant]
EP 0520722B1
· 1996
[cited by applicant]
EP 0787722A1
· 1997
[cited by applicant]
EP 0837063A1
· 1998
[cited by applicant]
WO WO9633980A1
· 1996
[cited by applicant]
WO WO9702266A1
· 1997
[cited by applicant]
WO WO9709433A1
· 1997
[cited by applicant]
WO WO9730034A1
· 1997
[cited by applicant]
WO WO9738983A1
· 1997
[cited by applicant]
WO WO9749688A1
· 1997
[cited by applicant]
WO WO9810767A2
· 1998
[cited by applicant]
WO WO9903854A1
· 1999
[cited by applicant]
WO WO0168709A1
· 2001
[cited by applicant]
WO WO0185207A2
· 2001
[cited by applicant]
WO WO02066470A1
· 2002
[cited by applicant]
WO WO03064383A2
· 2003
[cited by applicant]
WO WO2004067569A1
· 2004
[cited by applicant]
WO WO2005019429A2
· 2005
[cited by applicant]
WO WO2005090573A2
· 2005
[cited by applicant]
WO WO2005097211A2
· 2005
[cited by applicant]
WO WO2006122806A2
· 2006
[cited by applicant]
WO WO2007084786A1
· 2007
[cited by applicant]
WO WO2009036082A2
· 2009
[cited by applicant]
WO WO2009055730A1
· 2009
[cited by applicant]
WO WO2013074916A1
· 2013
[cited by applicant]
WO WO2013192294A1
· 2013
[cited by applicant]
WO WO2014031687A1
· 2014
[cited by applicant]
WO WO2014059173A2
· 2014
[cited by applicant]
WO WO2014153114A1
· 2014
[cited by applicant]
WO WO2015066262A1
· 2015
[cited by applicant]
WO WO2015123642A1
· 2015
[cited by applicant]
WO WO2015184228A1
· 2015
[cited by applicant]
WO WO2016019300A1
· 2016
[cited by applicant]
WO WO2016044605A1
· 2016
[cited by applicant]
WO WO2016126608A1
· 2016
[cited by applicant]
WO WO2017019848A1
· 2017
[cited by applicant]
WO WO2017025944A2
· 2017
[cited by applicant]
WO WO2017083700A1
· 2017
[cited by applicant]
WO WO2017205747A1
· 2017
[cited by applicant]
WO WO2017219916A1
· 2017
[cited by applicant]
WO WO2018031419A1
· 2018
[cited by applicant]
WO WO2018064076A1
· 2018
[cited by applicant]
WO WO2018132695A1
· 2018
[cited by applicant]
WO WO2018212770A1
· 2018
[cited by applicant]
WO WO2018220224A1
· 2018
[cited by applicant]
WO WO2019067328A1
· 2019
[cited by applicant]
WO WO2019079529A1
· 2019
[cited by applicant]
WO WO2019086512A1
· 2019
[cited by applicant]
WO WO2019091478A1
· 2019
[cited by applicant]
WO WO2019157440A1
· 2019
[cited by applicant]
WO WO2019191332A1
· 2019
[cited by applicant]
WO WO2019191334A1
· 2019
[cited by applicant]
WO WO2019191339A1
· 2019
[cited by applicant]
WO WO2019191340A1
· 2019
[cited by examiner]
WO WO2020114518A1
· 2020
[cited by applicant]
WO WO2020223550A1
· 2020
[cited by applicant]
WO WO2021003428A1
· 2021
[cited by applicant]
WO WO2021067875A1
· 2021
[cited by applicant]
WO WO2022036285A1
· 2022
[cited by applicant]
WO WO2022036287A1
· 2022
[cited by applicant]
WO WO2023010097A1
· 2023
[cited by applicant]
Aderem, “Phagocytosis and the Inflammatory Response,”
[cited by applicant]
Agaugue et al., “224. Development of Safer & Optimized CAR-T Cells Using Lentiviral Vectors,”
[cited by applicant]
Aggen et al., “Single-chain V(alpha)V(beta) T-cell receptors function without mispairing with endogenous TCR chains,”
[cited by applicant]
Albert et al., “αvβ5 integrin recruits the CrkII-Dock180-Rac1 complex for phagocytosis of apoptotic cells,”
[cited by applicant]
Alder et al., “Antibody responses of variable lymphocyte receptors in the lamprey,”
[cited by applicant]
Altman et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,”
[cited by applicant]
Arandjelovic et al., “Phagocytosis of apoptotic cells in homeostasis,”
[cited by applicant]
Baral et al., “Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor,”
[cited by applicant]
Barthelemy et al., “Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains,”
[cited by applicant]
Belzile et al., “Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer,”
[cited by applicant]
Blackburn et al., “Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection,”
[cited by applicant]
Blasius et al., “Intracellular Toll-like Receptors,”
[cited by applicant]
Burns et al., “A high molecular weight-melanoma associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas,”
[cited by applicant]
Castellano et al., “Membrane recruitment of Rac1 triggers phagocytosis,”
[cited by applicant]
Chen et al., “Fusion Protein Linkers: Property, Design and Functionality,”
[cited by applicant]
Chen et al., “TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis,”
[cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries,”
[cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,”
[cited by applicant]
Cordoba et al., “The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor,”
[cited by applicant]
Corey et al., “Novel engineered chimeric engulfment receptors trigger T cell effector functions against SIV-infected CD4+ T cells,” Mol Ther Methods Clin Dev. 28:1-10, Nov. 2022.
[cited by applicant]
Cortez-Retamozo et al., “Efficient Cancer Therapy with a Nanobody-Based Conjugate,”
[cited by applicant]
Delgado Tascón et al., “The granulocyte orphan receptor CEACAM4 is able to trigger phagocytosis of bacteria,”
[cited by applicant]
Dillon et al., “Annexin V Binds to Viable B Cells and Colocalizes with a Marker of Lipid Rafts upon B Cell Receptor Activation,”
[cited by applicant]
Dolezal et al., “ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and …
[cited by applicant]
Duclos et al., “Rab5 regulates the kiss and run fusion between phagosomes and endosomes and the acquisition of phagosome leishmanicidal properties in RAW 264.7 macrophages,”
[cited by applicant]
Engels et al., “Retroviral Vectors for High-Level Transgene Expression in T Lymphocytes,”
[cited by applicant]
Feng et al., “Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2,”
[cited by applicant]
Fesnak et al., “Engineered T Cells: The Promise and Challenges of Cancer Immunotherapy,”
[cited by applicant]
Frecha et al., “Advances in the Field of Lentivector-based Transduction of T and B Lymphocytes for Gene Therapy,”
[cited by applicant]
Genbank Accession No. NP_612388 (2006).
[cited by applicant]
Genbank Accession No. NP_848874 (2009).
[cited by applicant]
Gerber et al., “Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts,”
[cited by applicant]
Ghahroudi et al., “Selection and identification of single domain antibody fragments from camel heavy-chain antibodies,”
[cited by applicant]
Green et al., “Mitochondria and Apoptosis,”
[cited by applicant]
Greenberg et al., “Clustered syk tyrosine kinase domains trigger phagocytosis,”
[cited by applicant]
Greenberg, “Programmed cell death: A way of life for plants,”
[cited by applicant]
Guest et al., “The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens,”
[cited by applicant]
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,”
[cited by applicant]
Hanayama et al., “Identification of a factor that links apoptotic cells to phagocytes,”
[cited by applicant]
Hartt Meyers et al., “TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation,”
[cited by applicant]
Hayashi et al., “The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5,” Nature, 410(6832), Apr. 2001, pp. 1099-1103.
[cited by applicant]
Herrin et al., “Structure and specificity of lamprey monoclonal antibodies,”
[cited by applicant]
Hochreiter-Hufford et al., “Clearing the Dead: Apoptotic Cell Sensing, Recognition, Engulfment, and Digestion,”
[cited by applicant]
Hudecek et al., “Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells,”
[cited by applicant]
Hudecek et al., “The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity,”
[cited by applicant]
Hull et al., “The Mononuclear Phagocyte System in Homeostasis and Disease: A Role for Heme Oxygenase-1,”
[cited by applicant]
International Search Report and Written Opinion, mailed Aug. 19, 2019, for International Application No. PCT/US2019/024441, 13 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Feb. 6, 2018, for International Application No. PCT/US2017/053553, 13 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Jun. 28, 2019, for International Application No. PCT/US2019/024442, 12 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Jun. 7, 2019, for International Application No. PCT/US2019/024433, 13 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Mar. 25, 2019, for International Application No. PCT/US2018/052297, 11 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed May 29, 2019, for International Application No. PCT/US2019/024435, 14 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Jan. 25, 2022, for International Application No. PCT/US2021/046043, 17 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Dec. 14, 2021, for International Application No. PCT/US2021/046041, 17 pages.
[cited by applicant]
International Search Report and Written Opinion, mailed Feb. 4, 2022, for International Application No. PCT/US2021/046014, 21 pages.
[cited by applicant]
Jespers et al., “Aggregation-resistant domain antibodies selected on phage by heat denaturation,”
[cited by applicant]
Jolly, “9: Emerging Viral Vectors,”
[cited by applicant]
Jones et al., “Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes,”
[cited by applicant]
June, “Adoptive T cell therapy for cancer in the clinic,”
[cited by applicant]
Kao et al., “Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications,”
[cited by applicant]
Khogeer et al., “Antiphosphatidylserine antibodies as diagnostic indicators of antiphospholipid syndrome,”
[cited by applicant]
Kitchen et al., “Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice,”
[cited by applicant]
Kobayashi et al., “TIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells,”
[cited by applicant]
Kochenderfer et al., “Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor,”
[cited by applicant]
Krisky et al., “Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications,”
[cited by applicant]
Kruskal et al., “Phagocytic Chimeric Receptors Require Both Transmembrane and Cytoplasmic Domains from the Mannose Receptor,”
[cited by applicant]
Luo et al., “Development of genetically engineered CD4
[cited by applicant]
Maeda et al., “Engineering of Functional Chimeric Protein G-Vargula Luciferase,”
[cited by applicant]
Miksa et al., “A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester,”
[cited by applicant]
Misyurin, “Structure and Functions of Main Apoptosis Receptors and Ligands,” Russian Journal of Biotherapy 14(2):23-30, 2015.
[cited by applicant]
Miyanishi et al., “Identification of Tim4 as a phosphatidylserine receptor,”
[cited by applicant]
Moller-Tank et al., “Characterizing Functional Domains for TIM-Mediated Enveloped Virus Entry”, J. Virology, Jun. 2014, 88(12): 6702-6713).
[cited by applicant]
Moller-Tank et al., “Phosphatidylserine receptors: enhancers of enveloped virus entry and infection,” Virology 468-470:565-580, Nov. 2014.
[cited by applicant]
Morgan et al., “Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes,”
[cited by applicant]
Morrissey et al., “Chimeric antigen receptors that trigger phagocytosis,” eLife, 2018. (21 pages).
[cited by applicant]
Muller et al., “Spliceosomal Peptide P140 for Immunotherapy of Systemic Lupus Erythematosus: Results of an Early Phase II Clinical Trial,”
[cited by applicant]
Nakaya, “Research on Molecular Mechanisms of Engulfment of Apoptotic Cells”,
[cited by applicant]
Nguyen et al., “Heavy-chain antibodies in
[cited by applicant]
Nguyen et al., “The Specific Variable Domain of Camel Heavy-chain Antibodies is Encoded in the Germline,”
[cited by applicant]
Nishi et al., “Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity,”
[cited by applicant]
Nishi et al., “Tim4- and MerTK-Mediated Engulfment of Apoptotic Cells by Mouse Resident Peritoneal Macrophages,”
[cited by applicant]
Nix et al., “In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatement of Refractory B-Cell Malignancies”, Blood, American Society of Hematology, vol. 134, Nov. 2019, 4 pages.
[cited by applicant]
Ortiz et al., “The evolutionary history of the CD209 (DC-SIGN) family in humans and non-human primates,” Genes and Immunity, Jun. 2008, 2008(9), pp. 483-492.
[cited by applicant]
Park et al., “The Phosphatidylserine Receptor TIM-4 Does Not Mediate Direct Signaling,”
[cited by applicant]
Parmar et al., “The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition”, Translational Cancer Mechanisms and Therapy, Clinical Cancer Re…
[cited by applicant]
Penberthy et al., “Apoptotic cell recognition receptors and scavenger receptors,”
[cited by applicant]
Pfeifer et al., “Gene Therapy: Promises and Problems,”
[cited by applicant]
Portolano et al., “Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain “Roulette”,”
[cited by applicant]
Qin et al., “Prelinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22,” Molecular Therapy: Oncolytics, vol. 11, Dec. 2018, pp. 127-137.
[cited by applicant]
Ravichandran “Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums,”
[cited by applicant]
Rossi et al., “Genetic therapies against HIV,”
[cited by applicant]
Roux et al., “Structural analysis of the nurse shark (new) antigen receptor (NAR): Molecular convergence of NAR and unusual mammalian immunoglobulins,”
[cited by applicant]
Safdari et al., “Antibody humanization methods—a review and update,”
[cited by applicant]
Sandberg et al., “Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes,”
[cited by applicant]
Sato et al., “Enhancement of Fcγ Receptor-Mediated Phagocytosis by Transforming Mutants of Cbl1,”
[cited by applicant]
Scatchard et al., “The Attractions of Proteins for Small Molecules and Ions,”
[cited by applicant]
Schmitt et al., “T Cell Receptor Gene Therapy for Cancer,”
[cited by applicant]
Scholten et al., “Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells,”
[cited by applicant]
Schutters et al., “Phosphatidylserine targeting for diagnosis and treatment of human diseases,”
[cited by applicant]
Segawa et al., “An Apoptotic ‘Eat Me’ Signal: Phosphatidylserine Exposure,” Trends Cell Biol. 25(11):639-650, Nov. 2015.
[cited by applicant]
Sommermeyer, “Chimeric antigen receptor-modified T cells derived from defined CDS+ and CD4+ subsets confer superior antitumor reactivity in vivo,” Leukemia 30(2):492-500, Feb. 2016.
[cited by applicant]
Srivastava et al., “Engineering CAR-T Cells: Design Concepts,”
[cited by applicant]
Stone et al., “A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control,”
[cited by applicant]
Teplyakov et al., “Antibody modeling assessment II. Structures and models,”
[cited by applicant]
Vallabhapurapu et al., “Variation in human cancer cell external phosphatidylserine isregulated by flippase activity and intracellular calcium,”
[cited by applicant]
Verhoeyen et al., “Chapter 8: Lentiviral Vector Gene Transfer into Human T Cells,”
[cited by applicant]
Vincke et al., “General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold,”
[cited by applicant]
Walseng et al., “A TCR-based Chimeric Antigen Receptor,”
[cited by applicant]
Wang et al., “A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells,”
[cited by applicant]
Williamson et al., “Abstract A165: Engineering approaches to uncover the mechanism of apoptotic cell clearance by a conserved signaling system,”
[cited by applicant]
Williamson et al., “Abstract PR15: Engineering phagocytic signaling,” CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, New York, New York, Sep. 25-28, 2016. (4 pages).
[cited by applicant]
Williamson et al., “Cellular reconstitution of apoptotic cell clearance reveals a multi-step phosphorylation mechanism for Draper receptor triggering,” bioRxiv: 1-48, 2017. (58 pages).
[cited by applicant]
Williamson et al., “Spatial control of Draper receptor signaling initiates apoptotic cell engulfment,”
[cited by applicant]
Wilson, “Analyzing Biomolecular Interactions,”
[cited by applicant]
Wolff et al., “Monoclonal Antibody Homodimers: Enhanced Antitumor Activity in Nude Mice,”
[cited by applicant]
Wong K et al., “Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages,” Proc Natl Acad Sci USA 107(19) 8712-7, May 2010.
[cited by applicant]
Wälchli et al., “A Practical Approach to T-Cell Receptor Cloning and Expression,”
[cited by applicant]
Yang et al., “Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition,”
[cited by applicant]
Zaritskaya et al., “New flow cytometric assays for monitoring cell-mediated cytotoxicity,”
[cited by applicant]
Zhang et al., “Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity,”
[cited by applicant]
Zhao et al., “Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines,”
[cited by applicant]
George et al., “Third-generation anti-CD19 chimeric antigen receptor Tcells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)”, BMJ Open, Feb. 9, 2020, vo…
[cited by applicant]
Shakhov et al., “SMUCKLER/TIM4 is a distinct member of TIM family expressed by stromal cells of secondary lymphoid tissues and associated with lymphotoxin signaling”, European Journal of Immunology, Feb. 2004, vol. 34 N…
[cited by applicant]
Heo et al. “Niraparib: A Review in Ovarian Cancer.” Targeted Oncol. Aug. 2018, 13:533-539.
[cited by applicant]
Lai et al. “Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells.” Leukemia. Mar. 2018, 32, 801-808.
[cited by applicant]
Drew et al. “Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC).” Ann. Oncol. Oct. 2019, 30(5), v485-v486).
[cited by applicant]
Bobbin et al. “TIM-4-CER T Cells Elicit PS-Dependent Cytotoxic and Innate-Like Function and Synergize with Approved PARP Inhibitors in an Ovarian Cancer Model.” Poster M195 presented at the American Society of Gene and …
[cited by applicant]
Gura, “Systems for identifying new drugs are often faulty,” Science 278, No. 5340 (Nov. 7, 1997): 1041-42.
[cited by applicant]
Kaiser, “First Pass at Cancer Genome Reveals Complex Landscape,” Science 313, No. 5792 (Sep. 7, 2006): 1370.
[cited by applicant]
Jena et al., “Redirecting T-cell Specificity by Introducing a Tumor-specific Chimeric Antigen Receptor,” Blood 116, No. 7 (May 4, 2010): 1035-44.
[cited by applicant]
Tosello-Trampont et al. “Evidence for a Conserved Role for Crkll and Rac in Engulfment of Apoptotic Cells,” J. Biol. Chem. (Apr. 2001) 276:13797-13802.
[cited by applicant]
Barth et al., “Mediastinal (thymic) large B-cell lymphoma: where do we stand?” The Lancet Oncology (Apr. 2002), 3:229-234.
[cited by applicant]
“2022 ASGCT Annual Meeting Abstracts.” Molecular Therapy 30, No. 4 (May 2, 2022): 151 (Abstract #314). DOI: 10.1016/j.ymthe.2022.04.017.
[cited by applicant]